Table 1. Previously reported genetic variants associated with bladder cancer risk.
Results of meta-analyses of allelic OR estimates for the markers reported to achieve genome-wide significance25. Studies in Kiemeney et al. 20089 include: NBCS, LBCS, IBCS, TBCS, Sweden, Belgium, EEBCS, BBCS, ZBCS. Studies in Wu et al. 200911 include: NBCS, TXBCS1/2, New Hampshire, LBCS, IBCS, TBCS, Sweden, EEBCS, Belgium, BBCS, ZBCS, MSKCC. Studies in Rafnar et al 200919 include NBCS, IBCS, LBCS, Sweden, TBCS, EEBCS, Belgium, ZBCS, BBCS.
| Markera, risk alleleb, chrc, locationc and gened |
Groups of studies | Ne | Cases | Controls | Freq.f | Allelic OR (95%CI)g |
P valueh | ||
|---|---|---|---|---|---|---|---|---|---|
| rs9642880 [T] | Previously reported i 9 | 9 | 3,855 | 37,985 | 0.45 | 1.22 | 1.15 | 1.29 | 7.8E-12 |
| Chr 8q24.21: | Stage I | 5 | 3,525 | 5,108 | 0.45 | 1.21 | 1.13 | 1.29 | 4.6E-08 |
| 128787250 | Combined | 14 | 7,380 | 43,093 | 1.21 | 1.16 | 1.27 | 2.0E-18 | |
| MYC | |||||||||
| rs710521 [A] | Previously reported i 9 | 9 | 3,855 | 37,985 | 0.73 | 1.19 | 1.12 | 1.27 | 1.1E-07 |
| Chr 3q28: | Stage I | 5 | 3,519 | 5,110 | 0.72 | 1.15 | 1.07 | 1.25 | 3.3E-04 |
| 191128627 | Combined | 14 | 7,374 | 43,095 | 1.18 | 1.12 | 1.24 | 1.8E-10 | |
| TP63 | |||||||||
| rs2294008 [T] | Previously reported i 11 | 13 | 6,667 | 39,590 | 0.46 | 1.15 | 1.10 | 1.20 | 2.0E-10 |
| Chr 8q24.3: | Stage I | 5 | 3,529 | 5,115 | 0.45 | 1.08 | 1.01 | 1.16 | 2.2E-02 |
| 143758933 | Combined | 18 | 10,196 | 44,705 | 1.13 | 1.09 | 1.17 | 4.4E-11 | |
| PSCA | |||||||||
| rs401681 [C] | Previously reported i 19 | 9 | 4,147 | 34,988 | 0.54 | 1.12 | 1.06 | 1.18 | 5.1E-05 |
| Chr 5p15.33: | Stage I | 5 | 3,526 | 5,117 | 0.55 | 1.11 | 1.04 | 1.19 | 2.9E-03 |
| 1375087 | Combined | 14 | 7,673 | 40,105 | 1.11 | 1.07 | 1.16 | 5.0E-07 | |
| TERT-CLPTM1L | |||||||||
| rs798766 [T] | Previously reported i 10 | 11 | 4,580 | 45,269 | 0.19 | 1.24 | 1.17 | 1.32 | 9.5E-12 |
| Chr 4p16.3: | Stage I | 5 | 3,531 | 5,118 | 0.19 | 1.14 | 1.05 | 1.23 | 2.6E-03 |
| 1704037 | Combined | 16 | 8,111 | 50,387 | 1.20 | 1.14 | 1.26 | 3.9E-13 | |
|
TMEM129
TACC3-FGFR3 |
|||||||||
| Deletion Assay | Previously reported i 7,9 | 28 | 5,072 | 6,466 | 0.51 | 1.46 | 1.35 | 1.58 | 1.9E-21 |
| Chr 1p13.3 | Stage Ij | 4 | 2,480 | 3,222 | 0.49 | 1.49 | 1.33 | 1.68 | 3.7E-11 |
| GSTM1 | Combined | 32 | 7,552 | 9,688 | 0.53 | 1.47 | 1.38 | 1.57 | 5.0E-31 |
NCBI dbSNP identifier.
Risk allele shown in [].
Chromosome and NCBI Human Genome Build 36.3 location.
Gene neighborhood closest to the most notable SNP.
N: number of studies
Risk allele frequency in control populations.
Estimate assuming multiplicative odds model, OR, odds ratio; CI, 95% confidence interval.
1 d.f. trend test.
Summary estimates differ slightly from previously published because we used a fixed effects meta-analysis.
Data from SBCS was excluded from stage I because it had been included in the previous meta-analyses published in Garcia-Closas et al. 20057.. Data from NEBCS are reported separately (Unpublished data to appear in “GSTM1 null and NAT2 Slow Acetylation Genotypes, Smoking Intensity, and Bladder Cancer Risk: Results from the New England Bladder Cancer Case-Control Study and Meta-Analyses” by Moore LE, Baris D, Figueroa J, Garcia-Closas M, Karagas M, Schwenn M, Johnson A, Lubin J, Hein DW, Dagnall C, Colt J, Kida M, Jones M, Schned A, Cherela S, Chanock S, Cantor K, Silverman D, Rothman N)